Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

The antifungal compound butenafine eliminates promastigote and amastigote forms of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis

Texto completo
Autor(es):
Bezerra-Souza, Adriana ; Yamamoto, Eduardo S. ; Laurenti, Marcia D. ; Ribeiro, Susan P. ; Passero, Luiz Felipe D.
Número total de Autores: 5
Tipo de documento: Artigo Científico
Fonte: Parasitology International; v. 65, n. 6, A, p. 702-707, DEC 2016.
Citações Web of Science: 5
Resumo

The production of ergosterol lipid, important for the Leishmania membrane homeostasis, involves different enzymes. This pathway can be blocked to azoles and allylamines drugs, such as Butenafine. The aim of the present work was to evaluate the anti-leishmanicidal activity of this drug in 2 major species of Leishmania responsible for causing the American tegumentar leishmaniasis (L (L.) amazonensis and L (V.) braziliensis). Butenafine eliminated promastigote forms of L amazonensis and L braziliensis with efficacy similar to miltefosine, a standard anti-leishmania drug. In addition, butenafine induced alterations in promastigote forms of L amazonensis that resemble programmed cell death. Butenafine as well as miltefosine presented mild toxicity in peritoneal macrophages, however, butenafine was more effective to eliminate intracellular amastigotes of both L amazonensis and L braziliensis, and this effect was not associated with elevated levels of nitric oxide or hydrogen peroxide. Taken together, data presented herein suggests that butenafine can be considered as a prototype drug able to eliminate L amazonensis and L braziliensis, etiological agents of anergic diffuse and mucocutaneous leishmaniasis, respectively. (C) 2016 Elsevier Ireland Ltd. All rights reserved. (AU)

Processo FAPESP: 15/18746-4 - Avaliação da ação leishmanicida da Butenafina (in vitro) - reposicionamento de fármacos antifúngicos na leishmaniose
Beneficiário:Adriana Bezerra de Souza
Linha de fomento: Bolsas no Brasil - Iniciação Científica